CAR-macrophage
Showing 1 - 25 of 1,715
LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- (no location specified)
Sep 19, 2023
Advanced Solid Tumor Trial in Shanghai (B4T2-001 autologous CAR-T)
Recruiting
- Advanced Solid Tumor
- B4T2-001 autologous CAR-T
-
Shanghai, China/Shanghai, China
- +1 more
Oct 3, 2023
HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)
Recruiting
- HER2-positive
- +30 more
- CT-0508
-
Duarte, California
- +4 more
Feb 1, 2022
Toxicities in Children and Adults With Cancer
Active, not recruiting
- Macrophage Activation Syndrome
- Primary Hemophagocytic Lymphohistiocytosis
-
Bethesda, MarylandNational Cancer Institute (NCI)
Sep 17, 2022
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer Trial in New York, Houston (AIC100 CAR T
Recruiting
- Anaplastic Thyroid Cancer
- Relapsed/Refractory Poorly Differentiated Thyroid Cancer
- AIC100 CAR T Cells
-
New York, New YorkWeill Cornell Medical College
Feb 14, 2022
Multiple Myeloma Trial in Shanghai (GC012F injection)
Recruiting
- Multiple Myeloma
- GC012F injection
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Aug 1, 2022
Relapsed and/or Refractory B-cell Lymphoma Trial in Stanford, Baltimore, Houston (Cyclophosphamide, Fludarabine, KITE-363)
Recruiting
- Relapsed and/or Refractory B-cell Lymphoma
- Cyclophosphamide
- +2 more
-
Stanford, California
- +2 more
Aug 16, 2022
COVID-19 Trial in Brussels (Cytokines dosage, Complement dosage)
Completed
- COVID-19
- Cytokines dosage
- Complement dosage
-
Brussels, BelgiumCHU Brugmann
Sep 28, 2021
Relapsed/Refractory Large B-cell Lymphoma Trial in United States (Cyclophosphamide, Fludarabine, Lenzilumab)
Terminated
- Relapsed/Refractory Large B-cell Lymphoma
- Cyclophosphamide
- +3 more
-
Palo Alto, California
- +9 more
Aug 26, 2022
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)
Recruiting
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- TAK-007
- Chemotherapy Agents
-
Birmingham, Alabama
- +18 more
Aug 17, 2022
Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)
Recruiting
- Multiple Myeloma
- APRIL-BAFF-Bicephali CAR-T cells
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 14, 2023
Solid Tumors Trial in Kashiwa, Nishinomiya, Chuo-ku (TAK-103)
Recruiting
- Solid Tumors
- TAK-103
-
Kashiwa, Chiba, Japan
- +2 more
Mar 10, 2022
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
Malignant Tumors Trial in Chengdu (EBV mRNA vaccine)
Recruiting
- Malignant Tumors
- EBV mRNA vaccine
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Jan 27, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
Relapsed or Refractory Large B-cell Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed or Refractory Large B-cell Lymphoma
- Axicabtagene Ciloleucel
- +3 more
- (no location specified)
Jul 13, 2022
PET-CT Imaging in Relapsed/Refractory Acute Leukemias
Not yet recruiting
- B Cell
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 4, 2023
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the
Not yet recruiting
- Multiple Myeloma, Refractory
- Multiple Myeloma in Relapse
- Autologous CAR-T cell therapy expressing the BAFF-ligand.
-
Cleveland, OhioUniversity Hospitals Seidman Cancer Center
Jan 11, 2023
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)
Active, not recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Jan 18, 2023
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States
Recruiting
- Refractory Acute Myeloid Leukemia
- +4 more
- CD371-YSNVZ-IL18 CAR T cells
-
Basking Ridge, New Jersey
- +6 more
Aug 29, 2023
Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA CAR-T cells
-
Nanchang, Jiangxi, ChinaThe First Affiliated Hospital of Nanchang University
Aug 23, 2023
Leukemia, Lymphoma Trial in United States (SCRI-CAR22v2)
Recruiting
- Leukemia
- Lymphoma
- SCRI-CAR22v2
-
Los Angeles, California
- +4 more
Jan 18, 2023